Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | $27.00 → $2.00 | Outperform → In-line | Evercore ISI |
| 6/18/2024 | Buy → Hold | TD Cowen | |
| 6/18/2024 | $35.00 → $2.00 | Overweight → Equal Weight | Wells Fargo |
| 6/17/2024 | Buy → Neutral | Guggenheim | |
| 6/17/2024 | Buy → Neutral | BTIG Research | |
| 6/17/2024 | $41.00 → $3.00 | Outperform → Neutral | Wedbush |
| 3/25/2024 | $21.00 → $65.00 | Buy | Jefferies |
| 12/8/2023 | $35.00 | Equal Weight | Wells Fargo |
Evercore ISI downgraded Aerovate Therapeutics from Outperform to In-line and set a new price target of $2.00 from $27.00 previously
TD Cowen downgraded Aerovate Therapeutics from Buy to Hold
Wells Fargo downgraded Aerovate Therapeutics from Overweight to Equal Weight and set a new price target of $2.00 from $35.00 previously
—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi
Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of
Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D